#evaluate(de(' #AdditionalMetaTags# '))#
The loss of peripheral sensations, affecting diabetic peripheral neuropathy (DPN)(237 M patients), is a severe risk factor for altered gait biomechanics, balance impairment, increased falls risk and chronic pain development.
MYNERVA produced a peerless revolutionary non-invasive device to tackle all these symptoms, Leia: a groundbreaking device that offers a reprieve from the vicious cycle of pain and sensory loss. It is a wearable neurostimulating device able to restore the sense of touch and alleviate pain through pleasant, non-invasive AI-driven electrical stimulation, all within the familiar form factor of a sock.
The >>venture>> Grand Prize goes to MYNERVA (startupticker.ch)
Venture Leaders Medtech 2024: Captain's blog by Shelley Horn, Business Developer of MYNERVA (venturelab.swiss)
Venture Leaders Medtech roadshow 2024: A report from Boston (venturelab.swiss)
prototype
IP
clinical validation